Recently, Mursla Bio published a peer-reviewed paper in the interdisciplinary journal iScience, which is part of the esteemed Cell Press. The paper introduces a groundbreaking technology developed by Mursla Bio for analyzing sub-types of extracellular vesicles (EV) found in biofluids like blood. These EVs play a vital role in intercellular communication and have the potential to revolutionize disease diagnostics.
The paper titled “An electro-optical platform for the ultrasensitive detection of small extracellular vesicle sub-types and their protein epitope counts” presents Nano-Extracellular Omics Sensing (NEXOS), a novel and scalable technology that overcomes previous challenges related to the sensitive detection and quantification of EV proteins. The unique features of NEXOS allow for the exploration of new biological insights in liquid biopsies, making it easier to adopt EVs in clinical settings.
Mursla Bio is currently working on additional peer-reviewed papers to support its clinical study on liver cancer, which is expected to be completed later this year. The company aims to decode extracellular vesicles to develop curative treatments for cancer through its innovative blood test based on a novel modality. This test involves the analysis of liver-derived extracellular vesicles from blood, guided by artificial intelligence, to perform a non-invasive liver biopsy at any time.
Mursla Bio’s flagship test has the potential to replace ultrasound in the surveillance of liver cancer for approximately 10 million high-risk patients in Western countries. The company was recognized as the UK Life Sciences Innovator of 2023 in the Diagnostics and Precision Medicine category. For more information about Mursla Bio, visit their website at mursla.com or contact them at +44 (0) 1223 928 141 or email contact@mursla.com.
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/ZGIMM3GTHBDLNC6XLMNVM3C2EY.jpg)
